Source: Google NewsPublished on 2021-01-06
Related Articles:
- Monthly Research Review – December 2020 December 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- Monthly research review: February 2020 February 29, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Extrastriatal dopaminergic and serotonergic pathways in Parkinson's disease and in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. May 18, 2019 Related ArticlesExtrastriatal dopaminergic and serotonergic pathways in Parkinson's disease and in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging. 2019 May 16;: Authors: Pilotto A, di Cola FS, Premi E, Grasso R, Turrone R, Gipponi S, Scalvini A, Cottini E, Paghera B, Garibotto V, Rizzetti MC, Bonanni L, Borroni B, Morbelli S, Nobili F,…
- Scientists Engineer Tomato That Could Be Low-cost Source of Levodopa December 10, 2020 Scientists have created a tomato enriched in levodopa, or L-DOPA, a standard therapy for people with Parkinson’s disease. These tomatoes could represent a scalable, low-cost alternative L-DOPA source for Parkinson’s patients, particularly those in developing nations where treatment cost is prohibitive. Additional benefits of the engineered tomatoes include higher levels of amino acids, antioxidants, a longer shelf life, and more…
- Monthly Research Review – November 2019 November 30, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- [Video] The What, When, Why, & How of Treating and Managing Parkinson’s Dyskinesia October 28, 2020 Dyskinesia is an uncontrolled, involuntary muscle movement. Although it can be a stand-alone condition, in people with Parkinson’s, it is most often associated with long-term use of levodopa. Common symptoms of Parkinson’s dyskinesia include writhing or wriggling, fidgeting, rocking, and head bobbing. In this webinar, Dr. Irene Malaty answered questions including: What is Parkinson’s dyskinesia? What causes it? How does it…
- What I’ve Learned from Living with Parkinson’s Dyskinesia November 10, 2020 Everyone living with Parkinson’s experiences it differently, and people who experience dyskinesia are no different. The uncontrolled, irregular muscle movements that can be a side effect of carbidopa/levodopa impact people in various ways. It may cause wiggling motions, rocking and swaying, head bobbing, or other involuntary movements. And because dyskinesia affects people differently, techniques to manage and treat it vary.…
- What I’ve Learned from Living with Parkinson’s Dyskinesia November 11, 2020 Everyone living with Parkinson’s experiences it differently, and people who experience dyskinesia are no different. The uncontrolled, irregular muscle movements that can be a side effect of carbidopa/levodopa impact people in various ways. It may cause wiggling motions, rocking and swaying, head bobbing, or other involuntary movements. And because dyskinesia affects people differently, techniques to manage and treat it vary.…
- Monthly Research Review – November 2020 November 30, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- Monthly Research Review: Jaunary 2020 January 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2020. The post is divided into seven parts based on the type of research: Basic biology, Disease mechanism, Clinical research, New clinical trials, Clinical trial news, Other news, and…
- Monthy research review – December 2019 December 30, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- 2019: Year in review December 31, 2019 In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
- New Drug Shows Promise for Levodopa-Induced Dyskinesia March 12, 2019 All Science News articles summarize a research study and are not an official opinion, endorsement or position of the Parkinson’s Foundation’s. People with Parkinson’s disease (PD) commonly suffer from tremors and other movement symptoms, such as slowness and stiffness, caused by the loss of dopamine-producing nerve cells in an area of the brain called the substantia nigra An area of…
- Managing Chronic Pain, Part 1: Understanding a Shift in Perspective July 26, 2019 Pain and suffering are not the same. An internet search for “difference between pain and suffering” yields dozens of sites for writers and practitioners, like Ashley Pennewill and Ann Marie Gaudon, who extol the benefits to be gained from this conceptualization. The repeated message is that pain is the physical experience connected to insult and injury, while suffering is the…
- Gocovri Approved by FDA as 1st Treatment for Levodopa-induced Dyskinesia in Parkinson’s Patients August 25, 2017 The first treatment for levodopa-induced dyskinesia — the involuntary and jerky movements that afflict most Parkinson’s disease patients on this common therapy — was approved Thursday, Aug. 24, by the U.S. Food and Drug Administration. The therapy, Gocovri (amantadine) by Adamas Pharmaceuticals, is an long-acting and extended-release capsule, indicated for those receiving levodopa-based therapy, with or without other dopaminergic medications. These are…
- Beyond Clinic: How Can Imaging Help in the Diagnosis of Parkinson´s Disease? November 9, 2020 There is no simple way to diagnose the event-changing life of Parkinson´s disease (PD). Despite all the advancements in the biomarkers field, PD diagnosis still remains a clinical one based on the centrality of the motor features namely the presence of bradykinesia, rigidity, tremor and postural instability. However, non-motor symptoms are now considered in the PD diagnostic process as “supportive…
- Beyond Clinic: How Can Imaging Help in the Diagnosis of Parkinson´s Disease? November 9, 2020 There is no simple way to diagnose the event-changing life of Parkinson´s disease (PD). Despite all the advancements in the biomarkers field, PD diagnosis still remains a clinical one based on the centrality of the motor features namely the presence of bradykinesia, rigidity, tremor and postural instability. However, non-motor symptoms are now considered in the PD diagnostic process as “supportive…
- Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease. July 24, 2019 Related ArticlesImmunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease. Mov Disord. 2019 Jul 23;: Authors: Boi L, Pisanu A, Greig N, Scerba MT, Tweedie D, Mulas G, Fenu S, Carboni E, Spiga S, Carta AR Abstract BACKGROUND: Thalidomide and closely related analogues are used clinically for their immunomodulatory and antiangiogenic properties mediated by the inhibition of…
- What is Parkinson’s Disease Dyskinesia? June 12, 2018 Written by Dr. J. William Langston What is Parkinson’s Disease Dyskinesia? Dyskinesia literally means abnormal movement. Parkinson’s Disease (PD) Dyskinesia, often referred to as levodopa-induced dyskinesia, can be described as uncontrolled jerking, dance-like or wriggling movements. Symptoms range from minor tics to full-body movements. It can be a stand-alone condition; however, in people with Parkinson’s, it is most often associated with…
- How to Lead a Parkinson’s Dyskinesia Support Group November 4, 2020 Whether you have Parkinson’s dyskinesia or are the care partner of someone who does, leading a support group on this important topic allows you to both teach and learn about the common symptom and help others navigate its challenges. Here, we share ways to build your own knowledge base about Parkinson’s dyskinesia, discussion questions for your support group, and ideas for…
- The What, When, Why, & How of Treating and Managing Parkinson’s Dyskinesia October 28, 2020 Dyskinesia is an uncontrolled, involuntary muscle movement. Although it can be a stand-alone condition, in people with Parkinson’s, it is most often associated with long-term use of levodopa. Common symptoms of Parkinson’s dyskinesia include writhing or wriggling, fidgeting, rocking, and head bobbing. IN THIS EPISODE WITH DR. Irene Malaty, YOU WILL LEARN: What is Parkinson’s dyskinesia? What causes it? How does…
- NLX-112 Eases L-dopa Dyskinesia in Marmosets With Parkinson’s, Study Says March 5, 2020 An investigational therapy known as NLX-112 (befiradol) may hold promise to treat levodopa-induced dyskinesia, a complication of long-term levodopa therapy that affects people with Parkinson’s disease, a study found. The study, “The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets,” was published in Neuropharmacology. Motor symptoms of Parkinson’s disease include tremor; slow movement (bradykinesia); stiffness…